The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
- 30 November 2018
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (12), 1445-1452
- https://doi.org/10.1158/2326-6066.CIR-18-0487
Abstract
The explosion in novel cancer immunotherapies has resulted in extraordinary clinical successes in the treatment of multiple cancers. Checkpoint inhibitors (CPIs) that target negative regulatory molecules have become standard of care. However, with the growing use of CPIs, alone or in combination with chemotherapy, targeted therapies, or other immune modulators, a significant increase in immune-related adverse events (irAEs) has emerged. The wide-ranging and currently unpredictable spectrum of CPI-induced irAEs can lead to profound pathology and, in some cases, death. Growing evidence indicates that many irAEs are a consequence of a breakdown in self-tolerance, but the influence of genetics, the environment, and the mechanisms involved remains unclear. This review explores key questions in this emerging field, summarizing preclinical and clinical experiences with this new generation of cancer drugs, the growing understanding of the role of the immune response in mediating these toxicities, the relationship of CPI-induced autoimmunity to conventional autoimmune diseases, and insights into the mechanism of irAE development and treatment. (C) 2018 AACR.Keywords
This publication has 75 references indexed in Scilit:
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse eventsJournal of Translational Medicine, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceThe Journal of Experimental Medicine, 2011
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary, 2009
- Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathwayThe Journal of Experimental Medicine, 2006
- THE NOD MOUSE: A Model of Immune DysregulationAnnual Review of Immunology, 2005
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) MiceThe Journal of Experimental Medicine, 2003
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995